Skip to main content

Advertisement

SpringerLink
Log in

RRP22: a novel neural tumor suppressor for astrocytoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Astrocytomas are the most common neoplasm of the central nervous system. Although progress has been made, the survival rate of astrocytoma is still poor. Therefore, improving the prognosis of patients with astrocytomas relies on effective therapies that are directed against unique molecular aberrations. Previous studies have revealed that a novel member of the Ras superfamily, RRP22, which is located on chromosome 22 on the 12q site, is exclusively expressed in the central nervous system. RRP22 can be modified by farnesyl and down-regulated in a variety of neural tumor cell lines. In this study, we analyzed the mRNA level of RRP22 in normal brain tissues and astrocytomas using quantitative RT-PCR. Our results showed that the mRNA level in astrocytomas was significantly down-regulated compared to levels in normal tissues. As the pathological grade (World Health Organization (WHO) classification 2007) increased, the expression of RRP22 decreased. However, according to our research, there was no significant difference between malignant astrocytomas with pathological grades of III or IV. To investigate the possible effects of RRP22 on the biological behavior of glioma cells, we transfected RRP22 into a malignant cell line of astrocytomas, U251. We found that RRP22 inhibited growth, decreased invasiveness, and induced cell death. Thus, RRP22 is a special neural tumor suppressor for human astrocytomas, although further studies are needed to define the detailed mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Fuller GN, Scheithauer BW. The 2007 Revised World Health Organization (WHO) classification of tumours of the central nervous system: newly codified entities. Brain Pathol. 2007;17(3):304–7.

    Article  PubMed  Google Scholar 

  2. Wang L, et al. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol. 2006;24(10):1627–32.

    Article  PubMed  CAS  Google Scholar 

  3. Lymbouridou R, et al. Down-regulation of K-ras and H-ras in human brain gliomas. Eur J Cancer. 2009;45(7):1294–303.

    Article  PubMed  CAS  Google Scholar 

  4. Guha A, et al. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene. 1997;15(23):2755–65.

    Article  PubMed  CAS  Google Scholar 

  5. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. 2004;108(6):467–70.

    Article  PubMed  CAS  Google Scholar 

  6. Ligon AH, et al. Identification of a novel gene product, RIG, that is down-regulated in human glioblastoma. Oncogene. 1997;14(9):1075–81.

    Article  PubMed  CAS  Google Scholar 

  7. Yu Y, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A. 1999;96(1):214–9.

    Article  PubMed  CAS  Google Scholar 

  8. Zucman-Rossi J, Legoix P, Thomas G. Identification of new members of the Gas2 and Ras families in the 22q12 chromosome region. Genomics 1996 Dec 15 [cited 38 3]; 1996/12/15:247-54.

  9. Elam C, et al. RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential. Cancer Res. 2005;65(8):3117–25.

    PubMed  CAS  Google Scholar 

  10. Prigent SA, et al. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem. 1996;271(41):25639–45.

    Article  PubMed  CAS  Google Scholar 

  11. Cloughesy TF, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American brain tumor consortium study. J Clin Oncol. 2006;24(22):3651–6.

    Article  PubMed  CAS  Google Scholar 

  12. Lustig R, et al. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol. 2008;10(6):1004–9.

    Article  PubMed  CAS  Google Scholar 

  13. Lu W, et al. Suppression of invasion in human U87 glioma cells by adenovirus-mediated co-transfer of TIMP-2 and PTEN gene. Cancer Lett. 2004;214(2):205–13.

    Article  PubMed  CAS  Google Scholar 

  14. Lakka SS, et al. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene. 2002;21(52):8011–9.

    Article  PubMed  CAS  Google Scholar 

  15. Van Delft MF, et al. Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases. Cell Death Differ. 2010;17(5):821–32.

    Article  PubMed  Google Scholar 

  16. Tait SW, Green DR. Caspase-independent cell death: leaving the set without the final cut. Oncogene. 2008;27(50):6452–61.

    Article  PubMed  CAS  Google Scholar 

  17. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305(5684):626–9.

    Article  PubMed  CAS  Google Scholar 

  18. Noutsopoulos D, et al. VL30 retrotransposition signals activation of a caspase-independent and p53-dependent death pathway associated with mitochondrial and lysosomal damage. Cell Res. 2010;20(5):553–62.

    Article  PubMed  CAS  Google Scholar 

  19. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci U S A. 1996;93(25):14559–63.

    Article  PubMed  CAS  Google Scholar 

  20. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6(4):463–77.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The work was supported by National Natural Science Foundation of China Grants 30600636 (to Yanjin Wang).

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Xiangya Hospital of Central South University, 410078, Changsha, Hunan, People’s Republic of China

    Ruokun Chen, Liang Yang, Jiasheng Fang, Lei Huo, Mingyu Zhang, Fenghua Chen, Jinfang Liu, Jun Wu & Yanjin Wang

Authors
  1. Ruokun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiasheng Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lei Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mingyu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fenghua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jinfang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yanjin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiasheng Fang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, R., Yang, L., Fang, J. et al. RRP22: a novel neural tumor suppressor for astrocytoma. Med Oncol 29, 332–339 (2012). https://doi.org/10.1007/s12032-010-9795-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9795-6

Keywords

Search

Navigation